Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company was founded by Peter Laurence Molloy and Stephen Goodall on April 12, 2012 and is headquartered in Melbourne, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company